MAB Discovery to Produce Antibodies for GenmabGenetic Engineering NewsMunich, Germany-based company MAB Discovery has cut a deal with Genmab and its affiliate Genmab BV, under which it will produce antibodies for multiple Genmab targets to help Genmab …
|
Research and Markets: Therapy Class Overview: Rituximab Biosimilar
Business Wire (press release) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
RuiYi declares $15M Series B financing to advance monoclonal antibodies …News-Medical.netRuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent cor…
|
RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic …
MarketWatch RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi’s lead asset, RYI-008, a novel … San Diego’s RuiYi Raises $15M for Pipeline of Biologic TherapeuticsXconomy RuiYi banks $15M from A-list backers to amp up Chinese R&DFierceBiotech |
Final NICE backing for MabThera in rare conditionPMLiVEThe National Institute for Heath and Care Excellence (NICE) issued final guidance this week that gave the green light for MabThera (rituximab) to treat adults with a rare condition known as anti-ne…
Duke scientists identify antibodies in HIV immune responseDuke ChronicleResearchers found the difference between the two trials by specifying a subclass of antibodies linked to HIV elimination and decreased risk of infection in RV144 vaccines. Identify…
Dividend Derby: AbbVie Vs. PfizerMotley FoolBiogen reported solid phase 2b data last spring for daclizumab, and AbbVie and Bristol-Myers reported solid mid stage results for elotuzumab in previously treated myeloma patients last summer. Fool-worthy fin…
Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS …7thSpace Interactive (press release)IntroductionThe aim of this study was to evaluate the safety and efficacy of rituximab (RTX) in a large cohort of patients with rheumato…
Selexis SA Speak at the Human Antibodies and Hybridomas 2014 ConferencePR Web (press release)Selexis SA Speak at the Human Antibodies and Hybridomas 2014 Conference. Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced …
|
Fusion Antibodies Announces Lower Cost, Highly Flexible Antibody Production …
PR Web (press release) Fusion Antibodies have today announced revised pricing and new flexible packages for the production of Monoclonal Antibodies. The new work packages will provide an option to researches and SME’s who require benefits of a competitively priced service … |